Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • COVID-19
    • Safety
    • Drug Reference Sheet
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    When the Provider Becomes the Patient: What I Learned From COVID-19
    COVID-19
    When the Provider Becomes the Patient: What I Learned From COVID-19
    June 24, 2022
    The Case of the Late Head and Neck Lymphedema
    Clinical practice
    The Case of the Late Head and Neck Lymphedema
    June 20, 2022
    Our Patients Give Us Peace in Unexpected Circumstances
    Oncology nurse pride
    Our Patients Give Us Peace in Unexpected Circumstances
    June 17, 2022
    Behind Our Masks, I See You, I Hear You
    COVID-19
    Behind Our Masks, I See You, I Hear You
    June 10, 2022
    Connect With Your Patients on a Human Level as Well as a Healthcare Level
    Oncology nurse-patient relationship
    Connect With Your Patients on a Human Level as Well as a Healthcare Level
    June 03, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Treatments

    TNM Gets an Upgrade in Eighth Edition Staging Guidelines
    Clinical practice guidelines

    TNM Gets an Upgrade in Eighth Edition Staging Guidelines

    Nearly a century ago, cancer staging was a simple categorization of disease as either local, regional, or distant. Then in the 1940s, a French surgeon developed the concept for a staging system that uses the size of the primary tumor (T), its lymphatic involvement (N), and the presence of metastases (M) to stage a patient’s cancer based on the anatomic extent of the disease at the time of diagnosis.

    August 09, 2018
    FDA Approves Mogamulizumab-kpkc for Mycosis Fungoides or Sézary Syndrome
    U.S. Food and Drug Administration (FDA)

    FDA Approves Mogamulizumab-kpkc for Mycosis Fungoides or Sézary Syndrome

    On August 8, 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab-kpkc (Poteligeo) for adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.

    August 08, 2018
    Men May Have Greater Survival Benefit From Immune Checkpoint Inhibitors
    Immunotherapy

    Men May Have Greater Survival Benefit From Immune Checkpoint Inhibitors

    Researchers have found a significant difference in overall survival in men versus women receiving immune checkpoint inhibitors for advanced cancers. The findings from the systematic review and meta-analysis were reported in Lancet Oncology.

    August 08, 2018
    FDA Approves Ivosidenib for Relapsed or Refractory AML
    U.S. Food and Drug Administration (FDA)

    FDA Approves Ivosidenib for Relapsed or Refractory AML

    On July 20, 2018, the U.S. Food and Drug Administration (FDA) approved ivosidenib for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.

    July 20, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Ipilimumab for Certain Metastatic Colorectal Cancers

    On July 10, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to ipilimumab for use in combination with nivolumab for the treatment of patients 12 years of age and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

    July 12, 2018
    FDA Approves Encorafenib and Binimetinib in Combination
    U.S. Food and Drug Administration (FDA)

    FDA Approves Encorafenib and Binimetinib in Combination for Unresectable or Metastatic Melanoma With BRAF Mutations

    On June 27, 2018, the U.S. Food and Drug Administration (FDA) approved encorafenib and binimetinib (Braftovi and Mektovi) in combination for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.

    June 28, 2018
    Latest FDA Cancer Treatment Approvals Trend Toward New Indications
    U.S. Food and Drug Administration (FDA)

    Latest FDA Cancer Treatment Approvals Trend Toward New Indications

    What is unique about the most recent U.S. Food and Drug Administration (FDA) approvals in the oncology/hematology area is that almost all are for new indications of existing agents as opposed to new agents. This is not surprising because many of the agents target specific bioassays or tumor markers instead of a specific disease site. Oncology nurses need to be aware of the changes because treatments that they have become accustomed to giving for one indication may soon be given for others as well.

    June 28, 2018
    Monitoring Document for Monoclonal Antibodies
    Oncology nurse influence

    Oncology Nurse Develops Monitoring Document for Monoclonal Antibodies

    It’s a rote but important phrase: Necessity is the mother of invention. When a need presents itself, developing novel, inventive solutions can lead to important change. But inventive change doesn’t have to come on a massive scale: small inventions can still have a big impact.

    June 22, 2018
    ONS Congress

    Drug Offers Extended Adjuvant Treatment Option for HER2+ Metastatic Breast Cancer

    An estimated 266,120 new cases of invasive breast cancer and 40,920 related deaths will occur in the United States in 2018. Patients with distant disease have a poorer five-year relative survival rate (26.9%) compared with localized (98.9%) and regional (85.2%) disease. HER2+ breast cancer accounts for approximately 20%–25% of all breast cancer diagnoses, and this type of breast cancer is more common in younger women, decreasing in frequency with age across all stages.

    June 21, 2018
    Boosting T-Cell Memory Enhances Immunotherapy Effectiveness
    Immunotherapy

    Boosting T-Cell Memory Enhances Immunotherapy Effectiveness

    A combination of immunotherapies may increase the formation of memory T cells and lead to a more lasting response, according to findings from a study presented at the American Association for Cancer Research’s 2018 annual meeting.

    June 20, 2018
    CDK 4/6 Adverse Events
    Adverse events

    The Case of the CTCAE Assessment for CDK4/6 Adverse Events

    Mrs. Jones is a 66-year-old postmenopausal woman who developed left breast pain and a palpable mass. A mammogram and ultrasound showed a 4.6 cm mass with an enlarged axillary node. A core biopsy revealed invasive ductal carcinoma that is estrogen receptor positive, progesterone receptor positive, and HER2 negative. Positron-emission tomography and computed tomography scans revealed metastatic disease.

    June 19, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Bevacizumab in Combination With Chemotherapy for Ovarian Cancer

    June 14, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for Treatment of Relapsed or Refractory PMBCL

    June 14, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Mircera for Anemia Associated With Chronic Kidney Disease in Pediatric Patients on Dialysis

    On June 7, 2018, the U.S. Food and Drug Administration approved methoxy polyethylene glycol-epoetin beta (Mircera®, Vifor Pharma Inc.) for the treatment of pediatric patients aged 5–17 years on hemodialysis who are converting from another erythropoiesis-stimulating agent (ESA) after their hemoglobin level was stabilized with an ESA.

    June 12, 2018
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Venetoclax for CLL or SLL

    On June 8, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to venetoclax (Venclexta) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy.

    June 08, 2018
    Biosimilar to Pegfilgrastim
    U.S. Food and Drug Administration (FDA)

    FDA Approves First Biosimilar to Pegfilgrastim to Decrease Cancer Treatment Infection Risk

    On June 4, 2018, the U.S. Food and Drug Administration (FDA) approved pegfilgrastim-jmdb (Fulphila) as a biosimilar to pegfilgrastim (Neulasta) to decrease the chance of infection as suggested by febrile neutropenia in patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.

    June 05, 2018
    Which Breast Cancers Benefit from Treatment With Cyclin-Dependent Kinase 4/6 Inhibitor Treatment?
    Breast cancer

    Which Breast Cancers Benefit from Treatment With Cyclin-Dependent Kinase 4/6 Inhibitor Treatment?

    Which Breast Cancers Benefit from Treatment With Cyclin-Dependent Kinase 4/6 Inhibitor Treatment?

    A. Newly diagnosed DCIS  

    B. Metastatic, triple negative  

    C. Premenopausal, neoadjavant  

    D. ER+ metastatic

    May 31, 2018
    Here’s an Overview of the Types, Mechanisms, and Side Effects of Currently Approved Immunotherapies
    Immunotherapy

    Here’s an Overview of the Types, Mechanisms, and Side Effects of Currently Approved Immunotherapies

    Immunotherapy drugs fall into varying classes, each carrying its own mechanism of action and anticipated side effects. Although some side effects of immunotherapy may appear similar to those of chemotherapy (e.g., diarrhea, fatigue), they actually result from a totally different mechanism—meaning they require a different approach to management. Treating immunotherapy side effects as you would chemotherapy effects would likely result in patient harm.

    May 29, 2018
    fda
    U.S. Food and Drug Administration (FDA)

    FDA Reports Efficacy Issue for Patients Taking Pembrolizumab or Atezolizumab as Monotherapy to Treat Urothelial Cancer with Low Expression of PD-L1

    The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals, oncology clinical investigators, and the public about decreased survival associated with the use of pembrolizumab (Keytruda) or atezolizumab (Tecentriq) as monotherapy in clinical trials to treat patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1 (PD-L1).

    May 18, 2018
    Huntington Disease May Hold Key to Novel Cancer Treatment
    Research

    Huntington Disease May Hold Key to Novel Cancer Treatment

    The mutated huntington (HTT) gene causes the body to generate a class of small molecules that are toxic to cancer cells but not most healthy cells, according to the results of a new study published in EMBO Reports. The researchers went as far as to call it a “super assassin against all tumor cells.”

    May 16, 2018
    Manage Diarrhea in Patients Receiving Nerlynx® (Neratinib) Tablets
    Treatment side effects

    Manage Diarrhea in Patients Receiving Nerlynx® (Neratinib) Tablets

    Nerlynx® (neratinib) tablets, an oral kinase inhibitor, is approved by the U.S. Food and Drug Administration for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2-positive (HER2+) breast cancer, following adjuvant trastuzumab-based therapy.

    May 11, 2018
    FDA Approves Tisagenlecleucel for Adults with Relapsed or Refractory Large B-Cell Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Tisagenlecleucel for Adults with Relapsed or Refractory Large B-Cell Lymphoma

    On May 1, 2018, the U.S. Food and Drug Administration (FDA) approved tisagenlecleucel a CD19-directed genetically modified autologous T-cell immunotherapy, for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.

    May 03, 2018
    FDA
    U.S. Food and Drug Administration (FDA)

    FDA Approves Dabrafenib Plus Trametinib for Adjuvant Treatment of Melanoma With BRAF V600E or V600K Mutations

    On April 30, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to dabrafenib (Tafinlar ®) and trametinib (Mekinist®) in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.

    April 30, 2018
    Biosimilars Offer New Options for Treatment and New Concepts for Patient Education
    Biotherapy

    Biosimilars Offer New Options for Treatment and New Concepts for Patient Education

    The list of pharmacologic agents used in cancer care is expanding: chemotherapy, biotherapy, immunotherapy, targeted therapy, hormonal therapy, and now biosimilars. Part of being a nurse leader is recognizing trends in cancer care, changes on the horizon, and their impact on your patients and cancer treatment options. Biosimilars represent one such trend that affects providers’ approach to care and the education that oncology nurses must provide to patients and caregivers.

    April 24, 2018
    FDA Approves fostamatinib tablets for ITP
    U.S. Food and Drug Administration (FDA)

    FDA Approves Fostamatinib Tablets for ITP

    On April 17, 2018, the U.S. Food and Drug Administration approved fostamatinib disodium hexahydrate tablets for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

    April 17, 2018
    The Case of the Checkpoint Inhibitor Side Effects
    Immunotherapy

    The Case of the Checkpoint Inhibitor Side Effects

    John is a 62-year-old man diagnosed with metastatic non-small cell lung cancer (NSCLC). His tumor tested positive for high PD-L1 expression, and he began pembrolizumab treatment. John presents to the clinic for his third treatment and mentions that during the past week his arms and chest have been itchy and he has noticed a red, bumpy rash on his chest. When assessing John’s skin, you note a maculopapular rash on both of his upper extremities, anterior chest, and upper abdomen. What would you do?

    April 17, 2018
    FDA Approves Nivolumab Plus Ipilimumab Combination for Renal Cell Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Nivolumab Plus Ipilimumab Combination for Renal Cell Carcinoma

    On April 16, 2018, the U.S. Food and Drug Administration (FDA) granted approvals to nivolumab and ipilimumab in combination for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma.

    April 16, 2018
    FDA Approves Everolimus for TSC-Associated Partial-Onset Seizures
    U.S. Food and Drug Administration (FDA)

    FDA Approves Everolimus for TSC-Associated Partial-Onset Seizures

    On April 10, 2018, the U.S. Food and Drug Administration (FDA) approved everolimus tablets for oral suspension for the adjunctive treatment of adult and pediatric patients aged 2-years and older with tuberous sclerosis complex (TSC)-associated partial-onset seizures. Everolimus is also approved for two other manifestations of TSC: TSC-associated subependymal giant cell astrocytoma (SEGA) and TSC-associated renal angiomyolipoma.

    April 11, 2018
    Newly Approved Cancer Treatments Indicate Growing Role of Genomics and Oral Therapies
    U.S. Food and Drug Administration (FDA)

    Newly Approved Cancer Treatments Indicate Growing Role of Genomics and Oral Therapies

    It is becoming more commonplace for nurses to find orders for agents with which they are unfamiliar or quite possibly have never administered. Following is a summary of the latest new U.S. Food and Drug Administration (FDA) approvals or indications to keep you up to date in your practice. Of note, this summary contains the approval of yet another biosimilar in trastuzumab-dkst and rolapitant for chemotherapy-induced nausea and vomiting, which includes a safety alert. Early experiences with rolapitant, a NK-1 inhibitor, indicated a risk of hypersensitivity reactions.

    March 28, 2018
    FDA Approves Nilotinib for Pediatric Patients With Chronic Phase Ph+ CML
    U.S. Food and Drug Administration (FDA)

    FDA Approves Nilotinib for Pediatric Patients With Chronic Phase Ph+ CML

    On March 22, 2018, the U.S. Food and Drug Administration (FDA) approved nilotinib for pediatric patients 1 year of age or older with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor therapy.

    March 22, 2018
    FDA Approves Brentuximab Vedotin for Previously Untreated Stage III, IV Classical Hodgkin Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Brentuximab Vedotin for Previously Untreated Stage III, IV Classical Hodgkin Lymphoma

    On March 20, 2018, the U.S. Food and Drug Administration (FDA) approved brentuximab vedotin to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.

    March 20, 2018
    What Oncology Nurses Need to Know About Pharmacogenomics
    Clinical practice

    What Oncology Nurses Need to Know About Pharmacogenomics

    A subset of precision medicine, pharmacogenomics, is also growing exponentially, especially in oncology. Currently, 165 drugs or combinations are influenced by pharmacogenetics, and 58 of those are specific to oncology/hematology.

    March 13, 2018
    NCI Updates Cancer Trends Progress Report
    National Cancer Institute (NCI)

    NCI Updates Cancer Trends Progress Report

    The National Cancer Institute (NCI) has proactively shared new information and trends with the general public. Through its Cancer Trends Progress Report, NCI provides descriptions of research and data to help review past experiences and assist the agency in planning for future research funding.

    March 06, 2018
    Overview of Radiation Therapy for Cancer
    Radiation therapy

    Get an Overview of Radiation Therapy for Cancer

    Radiation therapy is a precise cancer treatment that targets tumor cells specifically and spares healthy surrounding tissues. Contrary to pharmacologic treatment methodologies, side effects are predominantly site-specific.

    February 27, 2018
    FDA Approves Abemaciclib As Initial Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer
    U.S. Food and Drug Administration (FDA)

    FDA Approves Abemaciclib As Initial Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer

    On February 26, 2018, the U.S. Food and Drug Administration (FDA) approved abemaciclib (Verzenio™) in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 HER2-negative advanced or metastatic breast cancer.

    February 26, 2018
    FDA Approves Durvalumab After Chemoradiation for Unresectable Stage III NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Approves Durvalumab After Chemoradiation for Unresectable Stage III NSCLC

    On February 16, 2018, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) for patients with unresectable stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

    February 16, 2018
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Apalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

    On February 14, 2018, the U.S. Food and Drug Administration (FDA) approved apalutamide (Erleada) for patients with non-metastatic castration-resistant prostate cancer.

    February 14, 2018
    FDA Clears Genomic Profiling Tests for Cancer Treatment
    U.S. Food and Drug Administration (FDA)

    FDA Clears Genomic Profiling Tests for Cancer Treatment

    Former National Institutes of Health (NIH) Director, Harold Varmus, when asked about cancer treatment, once said, “One of the major advances we’ve had as a result of cancer research is deep recognition of the complexity of cancer. It’s not one disease, it’s lots of different diseases. Every single cancer is different when you look at it on a genetic level.”

    January 29, 2018
    fda
    U.S. Food and Drug Administration (FDA)

    FDA Approves Lutetium Lu 177 Dotatate for Treatment of GEP-NETS

    On January 26, 2018, the U.S. Food and Drug Administration (FDA) approved lutetium Lu 177 dotatate a radiolabeled somatostatin analog, for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.

    January 26, 2018
    Immunotherapy Without Immune Cells
    Immunotherapy

    Immunotherapy Without Immune Cells May Be on the Horizon

    Researchers have generated immunotherapy in the laboratory using nonimmune cells. If the findings can be translated into treatment, it may reduce some of the immune-related adverse events that patients experience with today’s cancer immunotherapy treatments. The study was reported in Nature Chemical Biology.

    January 24, 2018
    drug holidays improve therapy for melanoma
    Research

    Drug Holidays May Improve Therapy for Treatment-Resistant Melanoma

    Taking an intentional drug holiday may improve patients’ response to reintroduction of treatment in drug-resistant melanoma, according to the results of a study published in Cancer Discovery.

    January 17, 2018
    FDA Approves First Biosimilar for Cancer Treatment, Among Other New Immunotherapy Dosing and Indications
    U.S. Food and Drug Administration (FDA)

    FDA Approves First Biosimilar for Cancer Treatment, Among Other New Immunotherapy Dosing and Indications

    Cancer treatment options continue to multiply as 2017 concludes, with the U.S. Food and Drug Administration (FDA) granting additional new drug approvals and broadening indications for others. Checkpoint inhibitors continue to explode on the scene with accelerated approvals for various indications. Treatment options for hematologic cancers are multiplying. Additionally, the first biosimilar for cancer treatment, bevacizumab-awwb, was approved as a biosimilar to bevacizumab.

    December 27, 2017
    peripheral neuropathy from chemo
    Research

    Discovery of Peripheral Neuropathy Cause May Lead to Preventive Treatments

    Researchers have found that taxane chemotherapies such as paclitaxel impede a protein called Bclw, which leads to the side effect of peripheral neuropathy. The study results were published in Neuron.

    December 20, 2017
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Bosutinib for Treatment of Newly-Diagnosed PH+ CML

    On December 19, 2017, the U.S. Food and Drug Administration granted accelerated approval to bosutinib for treatment of patients with newly-diagnosed chronic phase Philadelphia chromosome positive chronic myelogenous leukemia.

    December 19, 2017
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Grants Regular Approval to Cabometyx for First-Line Treatment of Advanced Renal Cell Carcinoma

    On December 19, 2017, the U.S. Food and Drug Administration (FDA) granted regular approval to cabozantinib for treatment of patients with advanced renal cell carcinoma (RCC).

    December 19, 2017
    San Antonio Breast Cancer Symposium

    Aggressive Treatment Needed for Locoregional Recurrence in Patients With Breast Cancer

    Researchers from Memorial Sloan Kettering Cancer Center in New York, NY, suggested that for women with locoregional recurrence (LRR) of breast cancer, contralateral axillary metastases should be treated aggressively for cure after excluding distant metastases. Challenges of and best practices for managing LRR was discussed at an education session during the San Antonio Breast Cancer Symposium on Tuesday, December 5.

    December 05, 2017
    roles of oncology nurses in research
    Research

    NCI Advancements Are Pushing Research Forward for Patients

    Former U.S. Senator Arlen Specter (R-PA) put partisanship aside to support federal funding for biomedical research. And, while battling cancer himself, he spoke about the National Institutes of Health (NIH) and its crucial role in finding treatments and cures. “Health is our nation’s number one asset. Without your health, you can’t do anything. I believe medical research should be pursued with all possible haste to cure the diseases and maladies affecting Americans. I have said many times that the NIH is the crown jewel of the federal government—perhaps the only jewel of the federal government.”

    December 04, 2017
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Ogivri as a Biosimilar to Herceptin

    On December 1, 2017, the U.S. Food and Drug Administration approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with HER2-overexpressing breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma).

    December 01, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Sunitinib Malate for Adjuvant Treatment of Renal Cell Carcinoma

    On November 16, 2017, the U.S. Food and Drug Administration (FDA) approved sunitinib malate (Sutent, Pfizer Inc.) for the adjuvant treatment of adult patients at high risk of recurrent renal cell carcinoma following nephrectomy.

    November 17, 2017
    New Imaging Shows Immunotherapy Results in Brain Cancer
    Immunotherapy

    New Imaging Better Shows Immunotherapy Results in Brain Cancer

    Researchers have developed a new approach for brain imaging that can better distinguish immune responses from tumor growth in people with glioblastoma. The findings were published in Proceedings of the National Academy of Sciences.

    November 15, 2017
    • First page « First
    • Previous page
    • Page 1
    • Page 2
    • Page 3
    • Current page 4
    • Page 5
    • Page 6
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • COVID-19
    • Safety
    • Drug Reference Sheet
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Cancer research
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2022 Oncology Nursing Society
     
    Back to Top ▲